Top Markets
#1 Akedo Akedo +89.15%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.04%
#4 Cross Cross +45.95%
#5 Black Phoenix Black Phoenix +34.04%
#6 Velvet Velvet +33.27%
#7 OVERTAKE OVERTAKE +20.49%
#8 Illuvium Illuvium +18.60%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.91%
#10 Cap Cap +15.95%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
GABY Inc. GABY Inc.

GABY Inc.

GABY
株式のランク #38694
GABY Inc., through its subsidiaries, is engaged in the manufacturing,... GABY Inc., through its subsidiaries, is engaged in the manufacturing, promotion, distribution, and retail sale of cannabis-related consumer packaged goods across the United States. The firm's offerings span a broad array of cannabis products, such as packaged flower, concentrated extracts, pre-rolled items, edibles, topical applications, tinctures, and other goods infused with or derived from cannabis or hemp. These cannabis products are marketed under the brand names Mankind, Kind Republic, Lulu's, 2Rise, and Dank Space. Established in 2003, the company was formerly known as Gabriella's Kitchen Inc. before rebranding as GABY Inc. in September 2019. GABY Inc. maintains its headquarters in Calgary, Canada.
株価
$0.00372038
最終同期: 2023-08-11
時価総額
$849.73K
変化（1日）
0.04%
変化（1年）
0.00%
国
CA
取引 GABY Inc. (GABY)

カテゴリー

Healthcare
GABY Inc.（GABY）の収益
Aug 2026 時点の収益 TTM: 0
GABY Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
GABY Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US